Orion Corporation Pharmaceutical Import Profile — Finland (DGFT 2022–2026)

Name: Orion Corporation Pharmaceutical Import Records from India — 15 Products, $19.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Orion Corporation — Pharmaceutical Importer Profile (2026) | 15 Products, $19.1M Trade | TransData Nexus

Orion Corporation

Pharmaceutical Importer · Finland · CNS & Psychiatric Focus · $19.1M Total Trade · DGFT Verified

Orion Corporation is a pharmaceutical importer based in Finland with a total trade value of $19.1M across 15 products in 8 therapeutic categories. Based on 564 verified import shipments from Indian Customs (DGFT) records, Orion Corporation is the #1 buyer in 1 product including Acetylsalicylic. Orion Corporation sources from 15 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 49.2% of imports.

Orion Corporation — Import Portfolio & Supplier Network

Orion Corporation import network — 15 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Orion Corporation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$40.2M	1,544	49.2%
Torrent Pharmaceuticals Limited	$18.0M	656	22.0%
Alembic Pharmaceuticals Limited

What Formulations Does Orion Corporation Import?

Formulation	Value	Ships
Levetiracetam tablets	$700.0K	14
Dicloxacillin sodium capsules	$635.3K	13
(dipyridamole modified release and	$600.0K	12
Dicloxacillin sodium capsules 500MG	$600.0K	12
Sertraline 100MG tablets(sertralin	$553.4K	14
Mirtazapine tablets 15MG(mirtazapin	$552.9K	18
Amlodipine tablets 5MG(amlodipin orion	$516.2K	19
Bupropion orion 150MG tabl 90's bot	$492.5K	26
Oribion 150 MG 1x30t orion	$412.5K	19
Levetiracetam tablets	$384.2K	8
Simvastatin tablets 20MG(simvastatin	$380.8K	9
Metforem 1g(metforem 1g	$380.0K	9
Venlafaxin orion 150 MG 7x14c fi	$372.1K	13
Pivmecillinam hydrochloride tablets	$364.0K	9
300007739 frimig fc tablets 50MG (6s	$350.0K	7

Orion Corporation imports 1,921 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 15 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Losartan	Cardiovascular	$3.2M	98	1.0%	15
2	Sertraline	CNS & Psychiatric	$2.9M	57	0.5%	4
3	Flucloxacillin	Advanced Antibiotics	$2.2M	63	3.5%	5
4	Citalopram	CNS & Psychiatric	$2.0M	88	0.8%	18
5	Amlodipine	Cardiovascular	$1.6M	32	0.0%	14
6	Escitalopram	CNS & Psychiatric	$1.5M	56	0.8%	18
7	Fluoxetine	CNS & Psychiatric	$1.1M	23	0.5%	6
8	Simvastatin	Cardiovascular	$1.1M	36	0.9%	6
9	Montelukast	Respiratory	$966.3K	45	0.6%	17
10	Loratadine	Antihistamines & Allergy	$800.0K	16	0.5%	6
11	Allopurinol	Lipid & Metabolism	$733.1K	17	0.1%	15
12	Lorazepam	CNS & Psychiatric	$282.4K	16	10.4%	3
13	Acetylsalicylic	Combination Drugs	$250.0K	5	5.7%	1
14	Salicylic	Combination Drugs	$250.0K	5	1.5%	5
15	Metoclopramide	Gastrointestinal	$242.1K	7	1.1%	8

Orion Corporation imports 15 pharmaceutical products across 8 categories into Finland totaling $19.1M. The company is the #1 buyer for 1 product: Acetylsalicylic.

Orion Corporation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Orion Corporation, established in 1917, is a Finnish pharmaceutical company headquartered in Espoo, Finland. The company specializes in the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Orion's extensive portfolio includes both proprietary and generic medicines, with a strong emphasis on therapeutic areas such as oncology, neurology, and respiratory diseases. The company operates globally, with a significant presence in Finland, where it maintains multiple manufacturing sites and research facilities.

In Finland, Orion plays a pivotal role in the pharmaceutical distribution network. Its subsidiary, Fermion, is responsible for the production of APIs, supplying both Orion's proprietary products and generic compounds to other pharmaceutical companies. This integration of API production and finished pharmaceutical manufacturing within Finland underscores Orion's commitment to maintaining a robust and self-sufficient supply chain. (production.orion.fi)

2Distribution Network

Orion Corporation's distribution network is primarily centered in Finland, with its main office located at Orionintie 1A, 02200 Espoo. The company operates several manufacturing and packaging facilities across the country, including sites in Kuopio, Salo, Turku, and Hanko. These facilities are strategically positioned to support efficient production and distribution of pharmaceutical products. For instance, the Salo site houses both packaging centers and warehouses, facilitating streamlined logistics operations. (production.orion.fi)

Orion's logistics capabilities are designed to ensure the timely and secure delivery of pharmaceutical products both domestically and internationally. The company's centralized manufacturing in Finland enhances its ability to manage supply chain operations effectively, ensuring a consistent supply of medicines to meet market demands. (production.orion.fi)

3Industry Role

Orion Corporation holds a significant position in Finland's pharmaceutical supply chain, functioning as a primary wholesaler and distributor. The company's vertically integrated operations, encompassing API production through its subsidiary Fermion and finished pharmaceutical manufacturing, enable it to maintain control over the entire supply chain. This integration allows Orion to ensure the quality and availability of its products, reinforcing its role as a key player in the Finnish pharmaceutical market. (production.orion.fi)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Orion Corporation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Orion Corporation's sourcing strategy reveals a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, Orion imported finished pharmaceutical formulations valued at $19.1 million USD from India, encompassing 564 shipments across 15 products in 8 therapeutic categories. The top five imported products—Losartan, Sertraline, Flucloxacillin, Citalopram, and Amlodipine—accounted for 61.9% of the total import value. This concentration indicates a strategic reliance on a select group of suppliers for key therapeutic areas.

The shipment data suggests a stable and ongoing relationship between Orion and its Indian suppliers, as evidenced by the consistent volume of imports over the years. However, the high concentration also implies potential risks associated with supply chain disruptions, currency fluctuations, and geopolitical factors that could impact the availability and cost of these imported products.

2Supply Chain Resilience

Orion Corporation's supply chain resilience concerning its Indian imports appears robust, given the consistent volume of imports and the established relationships with key suppliers. The company's diversified product portfolio, spanning multiple therapeutic categories, mitigates the impact of potential disruptions in any single product line. Additionally, Orion's domestic manufacturing capabilities in Finland provide a buffer against external supply chain challenges, ensuring continuity in product availability.

Importing Pharmaceuticals into Finland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Finland

1Regulatory Authority & Framework

In Finland, the Finnish Medicines Agency (Fimea) serves as the national competent authority responsible for regulating pharmaceuticals. Operating under the Ministry of Social Affairs and Health, Fimea's mandate includes ensuring the safety, efficacy, and quality of medicinal products available in Finland. Fimea oversees the marketing authorization process, monitors the safety of medicines, and provides guidance on pharmaceutical practices. (finlex.fi)

Key legislation governing pharmaceutical imports into Finland includes the Medicines Act (395/1987) and the Decree on Medicinal Products (693/1987). These regulations outline the requirements for importing, manufacturing, and distributing medicinal products within Finland. The marketing authorization pathway for Indian generics involves obtaining approval from Fimea, which assesses the quality, safety, and efficacy of the product before granting authorization for sale in Finland.

2Import Licensing & GMP

Import licensing requirements in Finland stipulate that all medicinal products, including those imported from India, must have a valid marketing authorization issued by Fimea. This ensures that imported products meet Finnish standards for quality, safety, and efficacy. Good Manufacturing Practice (GMP) certification is mandatory for manufacturers of imported pharmaceuticals. Fimea recognizes GMP certificates from the European Union, the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), provided they are deemed equivalent to EU GMP standards. Additionally, importers must hold a wholesale distribution authorization to legally distribute medicinal products within Finland.

Orion Corporation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Orion Corporation's focus on importing products in the Central Nervous System (CNS) & Psychiatric, Cardiovascular, and Advanced Antibiotics therapeutic categories aligns with the company's strategic emphasis on addressing critical health conditions prevalent in Finland. The substantial import values in these categories indicate a strong market demand and Orion's commitment to providing essential treatments. This strategy not only meets the therapeutic needs of the Finnish population but also positions Orion as a key supplier of vital medications in these areas.

2Sourcing Profile

Orion's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, focusing on products that complement its existing portfolio and address specific therapeutic needs. The company's preference for formulations over active pharmaceutical ingredients (APIs) suggests a strategic decision to leverage India's manufacturing capabilities while maintaining control over the final product quality and distribution. India's established reputation for producing high-quality generics makes it a suitable partner for Orion's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Orion Corporation

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Orion Corporation, particularly in therapeutic areas where Orion seeks to expand its product offerings. By understanding Orion's specific needs and regulatory requirements, Indian exporters can tailor their products to meet the demands of the Finnish market. Establishing partnerships with Orion could lead to increased market access and growth opportunities for Indian suppliers.

2Requirements & Qualifications

Indian exporters aiming to supply Orion Corporation and the Finnish market must ensure that their products have valid marketing authorizations from Fimea. Manufacturers must hold GMP certifications recognized by Fimea, such as EU GMP, WHO

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Orion Corporation

What products does Orion Corporation import from India?

Orion Corporation imports 15 pharmaceutical products across 8 categories. Top imports: Losartan ($3.2M), Sertraline ($2.9M), Flucloxacillin ($2.2M), Citalopram ($2.0M), Amlodipine ($1.6M).

Who supplies pharmaceuticals to Orion Corporation from India?

Orion Corporation sources from 15 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (49.2% of imports, $40.2M).

What is Orion Corporation's total pharmaceutical import value?

Orion Corporation's total pharmaceutical import value from India is $19.1M, based on 564 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Orion Corporation focus on?

Orion Corporation imports across 8 categories. The largest: CNS & Psychiatric (40.7%), Cardiovascular (30.7%), Advanced Antibiotics (11.7%).

Get Full Orion Corporation Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.